Faron Pharmaceuticals Oy (LSE:FARN) Total Assets : £8.81 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Total Assets?

Faron Pharmaceuticals Oy's Total Assets for the quarter that ended in Dec. 2023 was £8.81 Mil.

During the past 12 months, Faron Pharmaceuticals Oy's average Total Assets Growth Rate was -22.60% per year. During the past 3 years, the average Total Assets Growth Rate was -9.20% per year. During the past 5 years, the average Total Assets Growth Rate was 0.90% per year. During the past 10 years, the average Total Assets Growth Rate was 6.90% per year.

During the past 12 years, Faron Pharmaceuticals Oy's highest 3-Year average Total Assets Growth Rate was 48.10%. The lowest was -9.50%. And the median was 11.70%.

Total Assets is connected with ROA %. Faron Pharmaceuticals Oy's annualized ROA % for the quarter that ended in Dec. 2023 was 0.00%. Total Assets is also linked to Revenue through Asset Turnover. Faron Pharmaceuticals Oy's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Faron Pharmaceuticals Oy Total Assets Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Total Assets Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

8.66

7.57

11.20

9.80

8.81

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial															11.20	14.36	9.80	11.01	8.81

Faron Pharmaceuticals Oy Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Faron Pharmaceuticals Oy's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-13.061	+	21.866
	=	8.81

Faron Pharmaceuticals Oy's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-13.061	+	21.866
	=	8.81

Faron Pharmaceuticals Oy (LSE:FARN) Total Assets Explanation

Total Assets is connected with ROA %.

Faron Pharmaceuticals Oy's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (11.014	+	8.805)	/ 2 )
	=	0	/	9.9095
	=	0.00 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Faron Pharmaceuticals Oy's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (11.014	+	8.805)	/ 2 )
=	0	/	9.9095
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Faron Pharmaceuticals Oy Total Assets Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines